UTHR: Flat Base detected on 26 Feb 2026

United Therapeutics reported Q4 earnings of $364.3 million, or $7.70 per share, forming a flat base breakout pattern at $535.10 versus key resistance at $537.19. The pattern delivers strong technical quality: structure score of 15.0 (near-maximum), breakout score of 13.0, and volume score of 11.0, yielding an overall score of 86 with 76.93% win probability. Volume elevated at 3.13x average (1.05M shares vs. 335K 20-day average) confirms institutional accumulation. Shares soared 11.73% in pre-market trading following earnings. The measured move target is $558.29, implying 4.3% upside from current levels. Key support sits at $452.44 (18.4% below current price).

Earnings per share of $7.7 substantially exceeded the $7.1 consensus estimate by 8.45%, and United Therapeutics achieved a significant milestone by surpassing $3 billion in annual revenue for the first time in 2025, marking 11% growth. CEO Dr. Martine Rothblatt emphasized the company's commitment to double-digit revenue growth, projecting a path to $4 billion in annualized revenue by the end of 2027, and importantly, this guidance does not incorporate contributions from three upcoming product launches. Key near-term catalysts include TETON-1 data for IPF in the U.S. and Canada expected in late first quarter or early second quarter 2026, along with results from the ADVANCE OUTCOMES study of ralinepag in PAH. United Therapeutics unveiled Tresmi, a soft-mist treprostinil inhaler that the company says reduced coughing by up to 90% in human studies, with plans to file for PAH and ILD this year and commercially launch next year. The pattern forms immediately post-earnings with bullish momentum and strong biotech sector tailwinds.

The flat base breakout structure suggests accumulation before directional move. A successful breakout would confirm break above $537.19 resistance on continued volume expansion (ideally >1.0M shares daily). The measured move target of $558.29 represents the price objective, implying 4.3% gain. Historical win probability of 76.93% indicates strong odds of pattern success. Invalidation occurs on a close below $452.44 key support, which would negate the setup and suggest reversal to accumulation phase or downtrend. The pattern's high structure score (15.0) and moderate-to-strong volume support near-term upside execution within 2-4 weeks.

Q4 revenue of $790 million fell short of analyst expectations of $815.24 million, indicating execution headwinds despite earnings beat. The fourth-quarter revenue shortfall was largely attributed to Tyvaso nebulizer performance, and BofA Securities trimmed its fiscal 2026 revenue estimate by 1%. RSI of 74.58 signals overbought conditions, increasing pullback risk. CFO James Edgemond sold 21,000 shares on December 1st at $479.99, reducing his position by 72.06%, flagging insider selling pressure. Clinical trial data (TETON-1, ADVANCE OUTCOMES) expected Q1-Q2 2026 carry binary event risk. Morgan Stanley kept a Hold rating with a $447 target, well below current price, reflecting analyst caution. Beta of 0.27 (low volatility) may limit downside cushion if broader biotech sentiment shifts. Valuation elevated near 52-week highs warrants profit-taking.